STVN
Stevanato Group Spa
NYSE · Life Sciences Tools & Services
$15.50
+1.35 (+9.54%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 1.11B | 1.02B | 2.62B | 2.66B | 2.46B |
| Net Income | 118.59M | 97.59M | 284.91M | 245.63M | 251.38M |
| EPS | — | — | — | — | — |
| Profit Margin | 10.7% | 10.1% | 10.9% | 9.2% | 10.2% |
| Rev Growth | +9.4% | +9.4% | +13.3% | +4.0% | +22.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 495.11M | 495.11M | 654.73M | 579.44M | 635.38M |
| Total Equity | 1.62B | 1.62B | 1.64B | 1.94B | 2.00B |
| D/E Ratio | 0.31 | 0.31 | 0.40 | 0.30 | 0.32 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 174.42M | 151.50M | 492.60M | 513.68M | 453.60M |
| Free Cash Flow | — | — | 247.83M | 349.36M | 309.93M |